45 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Development of Potent and Selective Antagonists for the UTP-Activated P2Y
University of Bonn
Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.
Bristol-Myers Squibb Research
Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.
Bristol-Myers Squibb
4-Alkyloxyimino derivatives of uridine-5'-triphosphate: distal modification of potent agonists as a strategy for molecular probes of P2Y2, P2Y4, and P2Y6 receptors.
National Institute of Diabetes and Digestive and Kidney Diseases
Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.
Bristol-Myers Squibb
Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.
Bristol-Myers Squibb
Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.
Bristol-Myers Squibb Research and Development
Synthesis and structure-activity relationships of suramin-derived P2Y11 receptor antagonists with nanomolar potency.
University of Bonn
UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety.
Bar-Ilan University
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.
University of Bonn
Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold.
University of Bonn
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
University of Bonn
Identification of hydrolytically stable and selective P2Y(1) receptor agonists.
Bar-Ilan University
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide.
University of Bonn
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists.
Niddk
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Abbott Laboratories
Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists.
University of Bonn
Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor.
Inspire Pharmaceuticals
Novel nucleotide triphosphates as potent P2Y2 agonists with enhanced stability over UTP.
Ucb-Group
Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate.
National Institute of Diabetes and Digestive and Kidney Diseases
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
University of Bonn
Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor.
National Institute of Diabetes and Digestive and Kidney Diseases
Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors.
Bar-Ilan University
Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.
National Institute of Diabetes
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.
National Institute of Diabetes
Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates.
Inspire Pharmaceuticals
Synthesis and P2Y2 receptor agonist activities of uridine 5'-phosphonate analogues.
Ghent University
Boranophosphate isoster controls P2Y-receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues.
Bar-Ilan University
Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphated-ester modifications as selective agonists of the P2Y(4) receptor.
Niddk
Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors.
University of Bonn
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
National Institute of Diabetes and Digestive and Kidney Diseases
Identification of a new class of small molecule C5a receptor antagonists.
Wyeth Research
Molecular recognition in the P2Y(14) receptor: Probing the structurally permissive terminal sugar moiety of uridine-5'-diphosphoglucose.
National Institute of Diabetes and Digestive and Kidney Diseases
Synthesis and P2Y receptor activity of nucleoside 5'-phosphonate derivatives.
Ghent University
Design, synthesis and biological evaluation of suramin-derived dual antagonists of the proinflammatory G protein-coupled receptors P2Y
University of Bonn
Structure-Based Design of 3-(4-Aryl-1H-1,2,3-triazol-1-yl)-Biphenyl Derivatives as P2Y14 Receptor Antagonists.
National Institute of Diabetes and Digestive and Kidney Diseases
4-Alkyloxyimino-cytosine nucleotides: tethering approaches to molecular probes for the P2Y
National Institute of Diabetes and Digestive and Kidney Diseases
New iantherans from the marine sponge Ianthella quadrangulata: novel agonists of the P2Y(11) receptor.
University of Bonn
Current knowledge on the nucleotide agonists for the P2Y2 receptor.
China Pharmaceutical University
Synthesis and Evaluation of the First Fluorescent Antagonists of the Human P2Y
University Park Nottingham